Wells Fargo lowered its price target for Parker-Hannifin (NYSE: PH) to $950 from $980, while maintaining an Overweight rating, due to an updated EPS outlook of $33.00-$33.30 for 2027 based on pending acquisitions and tax assumptions. However, Truist raised its price target to $1,147 from $1,139 and reiterated a Buy rating, citing the company's strong third-quarter earnings beat and healthy order activity across various end markets. Parker-Hannifin specializes in motion and control technologies, with operations in Diversified Industrial and Aerospace Systems segments.

Bank of America expects its second-quarter trading revenue to increase by 15% year-over-year, driven by market volatility. CEO Brian Moynihan noted improvements in investment banking and anticipates low-teen growth in wealth management revenue. Consumer spending and credit quality remain strong despite inflation.

Bank of America analyst Justin Post has reiterated a "Buy" rating on Amazon.com (AMZN) stock with a $310 price objective. The positive outlook is driven by the healthier momentum in Amazon’s cloud business due to AI demand, increased profitability, and a growing backlog. The analyst also highlighted the reacceleration in the retail segment and the impact of AI on the shopping experience.

Alphabet Inc. (Class A) shares traded steadily on Nasdaq, supported by its accelerating AI rollout and fresh institutional buying. The stock is nearing its 52-week high, reflecting strong year-to-date performance and robust financial metrics. Analysts and investors continue to focus on Alphabet's pivotal role in the AI transition and its consistent profitability.

Waterloo Capital L.P. increased its stake in Walmart Inc. by 7.7% in Q4, making it their second-largest holding with 434,730 shares valued at $48.4 million. Despite concerns over executive departures and insider selling, Walmart reported solid Q4 earnings with revenue beating forecasts and reaffirmed its positive forward guidance. Analysts have a "Moderate Buy" rating for WMT with an average price target of $138.85.

Exxon Mobil Corporation (XOM) is highlighted as a top oil stock to buy amidst the US-Iran conflict, demonstrating strong financial performance and strategic deepwater investments. The company recently secured a significant deepwater completions contract in Nigeria and reported robust first-quarter earnings, leading analysts to maintain positive ratings and price targets. While acknowledging XOM's potential, the article also suggests considering AI stocks for higher, shorter-term returns.

Deutsche Bank, Barclays, and Jefferies have all raised their price targets on Marvell Technology, Inc. (MRVL) following a solid fiscal Q1 report and strong Q2 outlook, driven by data center revenue and AI-related bookings. Marvell reported Q1 adjusted EPS and revenue ahead of consensus estimates, with revenue growth expected to accelerate through fiscal 2027.

Old National Bancorp (NASDAQ:ONB) is set to trade ex-dividend in four days, with a payment of US$0.145 per share. The company's dividend appears sustainable due to a modest payout ratio of 29% of profit and a five-year earnings per share growth of 7.0% per annum. While dividend growth has been slow at 1.9% per year over the past decade, the underlying financial health suggests the dividend is affordable and the company reinvests a significant portion of its profits for future prospects.

Match Group Inc. shares remained stable on Nasdaq, trading at around USD 30 on May 29, 2026, as investors assessed the company's latest quarterly update and the dynamics of the online dating sector. The stock is listed under the ticker MTCH and is available for German investors on platforms like Tradegate. The company's core business model relies on premium subscriptions and in-app features across its portfolio of dating apps, including Tinder, Hinge, and Match, with future catalysts tied to subscriber growth and product innovation.

Johnson & Johnson (JNJ) announced late-stage clinical trial results for its prostate cancer drug apalutamide. The study found that combining apalutamide with hormone therapy before and after surgery improved outcomes for men with high-risk localized or locally advanced prostate cancer. This suggests a potential expansion for apalutamide's use into earlier treatment stages, possibly setting a new standard of care.